- Institution: Stanford Univ Med Ctr Lane Med Lib/Periodical Dept/Rm L109
- Sign In as Member / Individual
Neuronal Nicotinic Receptor Subtypes: DEFINING THERAPEUTIC TARGETS
Table 1.
Nicotinic compounds under development
| Compound | Primary Disease Target/Drug Property | Subtype Preference | Development Stage |
|---|---|---|---|
| 1 Abbreviations are: ABT, Abbott Labs; AZD, Astra-Zeneca; MEM, Memory Pharmaceuticals; SSR, Sanofi Synthelabo; TC, Targacept; ACh, acetylcholine; NR, nicotinic receptor. | |||
| 2 Discontinued clinical development in the U.S. | |||
| ABT1 -089 | Alzheimer’s disease; ADHD; neuroprotection | α4 β2 | Pre-clinical |
| ABT-594 | Analgesia; high-affinity agonist | α4 β2 | Phase II |
| AZD0328 | Alzheimer’s disease | α7 | Discontinued2 |
| MEM-3454 | Alzheimer’s disease; schizophrenia; neuroprotection | α7 | Pre-clinical |
| SSR 180711 | Neurodegenerative diseases | α7 | Pre-clinical |
| TC-2559 | Dopamine releaseHigh-affinity NRPre-clinical | ||
| TC-1698 | Alzheimer’s disease; neuroprotection | α7 | Pre-clinical |
| TC-1734 | Cognition enhancement in the elderly/ACh release | α4 β2 | Phase II |
| TC-1827 | Alzheimer’s disease/Mild cognitive impairment | α4 β2 | Pre-clinical |
| TC-5231 | Attention deficit-hyperactivity disorder | Phase II | |
| TC-2696 | Pain | α4 β2 | Phase I |
